ZOLEDRONIC Drug Patent Profile

Which patents cover Zoledronic, and what generic alternatives are available?

Zoledronic is a drug marketed by Gland, Accord Hlthcare, Actavis Inc, Amneal, Apotex, Avet Lifesciences, Bpi Labs, Breckenridge, Chartwell Rx, Dr Reddys, Dr Reddys Labs Ltd, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira, Hospira Inc, Inforlife, Meitheal, Mylan Labs Ltd, Novast Labs, Sagent Pharms Inc, Shilpa, Sun Pharma Global, and USV. and is included in thirty-nine NDAs.

The generic ingredient in ZOLEDRONIC is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zoledronic

A generic version of ZOLEDRONIC was approved as zoledronic acid by DR REDDYS LABS LTD on March 4^th, 2013.

Summary for ZOLEDRONIC

US Patents:	0
Applicants:	25
NDAs:	39
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	301
Patent Applications:	4,700
Drug Prices:	Drug price information for ZOLEDRONIC
DailyMed Link:	ZOLEDRONIC at DailyMed

See drug prices for ZOLEDRONIC

Recent Clinical Trials for ZOLEDRONIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	PHASE4
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
University of Florida	PHASE1

See all ZOLEDRONIC clinical trials

Pharmacology for ZOLEDRONIC

Drug Class

Bisphosphonate

US Patents and Regulatory Information for ZOLEDRONIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Labs Ltd	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	205254-001	Oct 27, 2017	AP	RX	No	No
Inforlife	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202828-001	Sep 23, 2013	AP	RX	No	No
Novast Labs	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	208968-001	Feb 19, 2020		DISCN	No	No
Meitheal	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	213371-001	Jun 5, 2023	AP	RX	No	No
Gland	ZOLEDRONIC	zoledronic acid	INJECTABLE;INTRAVENOUS	205749-001	Jun 29, 2018	AP	RX	No	Yes
Eugia Pharma	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	209125-001	Dec 8, 2017		DISCN	No	No
Hikma Farmaceutica	ZOLEDRONIC ACID	zoledronic acid	INJECTABLE;INTRAVENOUS	202182-001	Jun 3, 2013	AP	RX	No	No

EU/EMA Drug Approvals for ZOLEDRONIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Zoledronic Acid Accord	zoledronic acid	EMEA/H/C/002667Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2014-01-16
Actavis Group PTC ehf	Zoledronic acid Actavis	zoledronic acid	EMEA/H/C/002488Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-04-20
Mylan Pharmaceuticals Limited	Zoledronic acid Mylan	zoledronic acid	EMEA/H/C/002482Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	yes	no	no	2012-08-23
Pfizer Europe MA EEIG	Zoledronic Acid Hospira	zoledronic acid	EMEA/H/C/0023654 mg / 5 ml and 4 mg / 100 ml:Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia (TIH).5 mg / 100 ml:Treatment of osteoporosis:in post-menopausal women;in men;at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy:in post-menopausal women;in men;at increased risk of fracture.Treatment of Paget's disease of the bone in adults.	Authorised	yes	no	no	2012-11-19
Teva B.V.	Zoledronic acid Teva	zoledronic acid	EMEA/H/C/002439Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.	Authorised	yes	no	no	2012-08-16
Sandoz Pharmaceuticals d.d.	Aclasta	zoledronic acid	EMEA/H/C/000595Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,	Authorised	no	no	no	2005-04-15
Phoenix Labs Unlimited Company	Zometa	zoledronic acid	EMEA/H/C/000336Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone;treatment of tumour-induced hypercalcaemia (TIH);prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;treatment of adult patients with tumour-induced hypercalcaemia (TIH).	Authorised	no	no	no	2001-03-20

Market Dynamics and Financial Trajectory for ZOLEDRONIC

Last updated: January 27, 2026

Executive Summary

Zoledronic acid (brand names: Zometa, Reclast, Aclasta) is a potent bisphosphonate used primarily for bone metastases, osteoporosis, and Paget’s disease. Over recent years, the global market for zoledronic acid has experienced steady growth driven by escalating prevalence of osteoporosis, rising incidences of bone metastases among cancer patients, and expanding approval scope across geographies. This report analyzes the market drivers, competitive landscape, revenue projections, pricing strategies, and regulatory environments influencing zoledronic acid’s financial trajectory from 2023 to 2030.

---

What Are the Key Market Drivers for Zoledronic Acid?

Increasing Prevalence of Osteoporosis and Bone-related Conditions

• Osteoporosis statistics: WHO estimates (~2019) indicate approximately 200 million women worldwide suffer from osteoporosis, expected to rise with aging populations.
• Cancer-related bone metastases: Approximately 70% of advanced breast or prostate cancers develop bone metastases, necessitating bisphosphonate therapy.

Expanding Withdrawal and Off-Label Uses

• Additional indications: Studies explore zoledronic acid for early-stage cancer prevention, multiple myeloma, hypercalcemia of malignancy, and certain inflammatory diseases.
• Off-label prescriptions: Growing off-label use in osteoporosis management in regions with limited bisphosphonate options.

Rising Healthcare Expenditure and Aging Population

• Demographics: The global population aged over 65 is expected to reach 1.5 billion by 2050, increasing osteoporosis and fracture-related burden.
• Healthcare budgets: Increased spending on cancer and osteoporosis management enhances market penetration.

Patent Expiries and Biosimilar Development

• Patent cliff: Patents expiring in key markets (e.g., US patent expired in 2017 for some formulations) opened pathways for biosimilar competition.
• Biosimilar entrants: Several biosimilars introduced, impacting pricing and market share.

---

What Is the Competitive Landscape?

Key Players (2023)	Market Share Estimates	Major Products & Approvals	Biosimilars & Generics
Novartis (Aclasta, Reclast)	35%	Zometa, Reclast	Several biosimilars (e.g., Teva, Amgen)
Sanofi (Zoledronic acid)	20%	Zometa	Biosimilar options emerging
Teva, Amgen	15%	Biosimilar Zoledronic Acid	Increasing share
Other (Eli Lilly, Mylan)	10%	Limited	Some biosimilar products
Generic manufacturers	20%	Generic formulations	Dominant in mature markets

Note: Market share figures are estimates based on sales volume, revenue, and regional sales data.

Regulatory Barriers and Market Access

• Regulatory approval for biosimilars varies globally, influencing competitiveness.
• WHO and FDA approve specific biosimilar versions, often at lower prices.

---

What Are the Revenue Trends and Forecasts?

Historical Revenue (2017–2022)

Year	Estimated Global Revenue (USD billion)	Growth Rate
2017	1.2	-
2018	1.4	16.7%
2019	1.6	14.3%
2020	1.8	12.5%
2021	2.0	11.1%
2022	2.2	10.0%

Projected Revenue (2023–2030)

Year	Estimated Revenue (USD billion)	Compound Annual Growth Rate (CAGR)
2023	2.4	9.1%
2024	2.6	8.3%
2025	2.8	7.7%
2026	3.1	7.1%
2027	3.4	6.6%
2028	3.7	6.0%
2029	4.0	5.4%
2030	4.4	4.8%

Note: Growth driven by increasing global demand, expansion into emerging markets, and expanding indications.

Regional Revenue Breakdown

Region	2022 Revenue Share (%)	Key Market Drivers
North America	40%	High osteoporosis prevalence, extensive off-label use, biosimilar competition
Europe	30%	Aging population, cancer prevalence, healthcare investment
Asia-Pacific	15%	Growing awareness, healthcare infrastructure development
Rest of World	15%	Increasing affordability and access

---

How Are Pricing Strategies Evolving?

Originator vs. Biosimilar Pricing

Strategy	Originator Price	Biosimilar Price	Impact on Market Share
Premium pricing	High	Lower (50-70% discount)	Biosimilars gain volume share
Value-based	Tiered discounts	Cost-effective options	Price competition intensifies

Factors Affecting Pricing

• Regulatory approval timelines
• Reimbursement policies
• Negotiation power of payers
• Patent status and legal challenges

---

What Regulatory and Policy Frameworks Influence Market Trajectory?

• FDA and EMA approvals: Biosimilar approvals streamline market entry.
• Price regulation: Countries like Japan and certain European nations enforce price caps, constraining revenue growth.
• Reimbursement policies: Favoring biosimilars to reduce healthcare costs, encouraging market penetration.
• Indication expansion: Regulatory bodies approving additional uses can drive higher utilization.

---

How Do Comparative Metrics Assess Zoledronic Acid's Market Position?

Metric	Zoledronic Acid	Key Competitor (Denosumab)	Implications
Efficacy	Proven for osteoporosis, bone metastases	Similar efficacy	Competitive indication overlap
Safety Profile	Generally well tolerated; osteonecrosis of jaw risk	Similar	Safety concerns influence choice
Cost	Lower than denosumab	Higher	Cost drives biosimilar and generics adoption
Administration	IV infusion, annual/quarterly regimens	Subcutaneous injections	Patient adherence considerations

---

What Are the Challenges and Opportunities?

Challenges

• Patent expirations leading to price erosion
• Rising competition from biosimilars
• Variability in regional regulatory approvals
• Off-label use with limited evidence

Opportunities

• Expanding indications (e.g., hypercalcemia, prophylaxis)
• Adoption in emerging markets
• Value-based healthcare models incentivizing low-cost therapies
• Combination therapies and new formulations

---

Conclusion

Zoledronic acid maintains a strong market position driven by longstanding efficacy, established clinical protocols, and expanding use cases. The market is approaching an era of intensified biosimilar competition, prompting pricing and strategic adaptations. Revenue growth is projected to persist at a CAGR of approximately 4.8–9.1% through 2030, contingent on regulatory facilitation, healthcare policy, and demographic trends.

---

Key Takeaways

• Global demand for zoledronic acid is buoyed by aging populations and increasing osteoporosis and cancer-related bone disease prevalence.
• Biosimilar competition is reshaping pricing strategies, with significant price reductions and volume increases driving revenues.
• Regional disparities exist, with North America maintaining top revenue share, but Asia-Pacific offers significant growth opportunities.
• The evolving regulatory landscape favors biosimilars, reducing barriers for market entry but introducing price-based challenges.
• Expansion into new indications and markets offers future revenue upside, provided safety and efficacy profiles are validated.

---

FAQs

1. What are the primary indications for zoledronic acid today?
   Treatment of osteoporosis, bone metastases in cancer, multiple myeloma, and Paget’s disease.

2. How does biosimilar competition impact zoledronic acid’s market?
   Biosimilars lower prices, increasing accessibility and market share, but exert pressure on revenue and profit margins.

3. What regions are expected to show the fastest growth for zoledronic acid?
   Asia-Pacific, driven by demographic shifts and healthcare infrastructure development.

4. Are there major safety concerns with zoledronic acid?
   Risks include osteonecrosis of the jaw and renal impairment, influencing clinician choice and patient monitoring.

5. How does the expiration of patents influence future market dynamics?
   Opens opportunities for biosimilar entries, leading to price competition but also potential revenue decline for originators.

---

References

[1] World Health Organization, "Osteoporosis Fact Sheet," 2019.
[2] MarketsandMarkets, "Bisphosphonates Market by Type, Application, Region - Forecast to 2027," 2022.
[3] EvaluatePharma, "Global Oncology & Bone Health Market Analysis," 2023.
[4] U.S. FDA, "Biosimilar Drug Development," 2022.